SOURCE: Alzheimer's Drug Discovery Foundation

July 18, 2007 09:00 ET

Alzheimer's Drug Discovery Foundation and The Association for Frontotemporal Dementias Create New Collaborative Grant Award Program

NEW YORK, NY--(Marketwire - July 18, 2007) - The Alzheimer's Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Dementias (AFTD) are pleased to announce a new grant award program entitled Frontotemporal Dementia Drug Discovery. This three-year collaborative program will provide a total of $900,000 to support academic and biotechnology industry scientists worldwide conducting drug discovery research on innovative therapies for frontotemporal dementia (FTD).

The program seeks to catalyze novel approaches to FTD drug discovery. An annual total of $300,000 will be awarded in grants averaging $100,000 per scientist. ADDF will be the administrator of the program supported by a Scientific Review Committee comprised of leading experts from the ADDF and AFTD Scientific Review Boards. Scientists will be invited to apply through an online application process available at The deadline for the first-year grant submission is October 15, 2007, and funding will be awarded April 15, 2008.

"We are grateful for AFTD's commitment to advancing the discovery and development of new treatments for FTD," remarked ADDF Executive Director Howard Fillit, MD, who will lead this research effort. "Their dedication and support enables the ADDF to broaden its programming, fund more scientists, and make an even greater contribution to bridging the global funding gap for FTD drug discovery research that will ultimately improve the lives of thousands of people."

"This program brings not only hope for a treatment, but it also captures energy building from recent scientific advances in the field and leverages it to new heights," stated Philip Lovett, a member of the AFTD Board of Directors. "We need to keep this momentum going and ensure that these findings are translated from the lab to the clinic as soon as possible in order to provide desperately-needed help to those patients and families who are coping with FTD."

About Frontotemporal Dementia (FTD)

Frontotemporal dementia (FTD) is a group of related conditions that share many clinical features and all result from progressive degeneration of the anterior temporal and frontal lobes of the brain. It is the second leading cause of presenile dementia after Alzheimer's Disease. The hallmark of FTD is a gradual decline in behavior and/or language that strikes individuals in their mid-40s to 60s, in the prime of life. As the disease advances, these deficits cause significant impairment in social and/or occupational functioning, thereby increasing dependency on caregivers. Currently, there are no treatments for FTD, which is why this drug discovery program is so essential for the patients and families affected by this disease.

About the Alzheimer's Drug Discovery Foundation (ADDF)

The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity established in 2004 to expand upon the programs initiated by the Institute for the Study of Aging (ISOA), a private foundation founded by the Estee Lauder family in 1998. Our sole mission is to accelerate drug discovery research to prevent, treat and cure Alzheimer's disease, related dementias and cognitive aging through venture philanthropy. To date, ADDF and ISOA have awarded $28.7 million for 195 research programs and conferences worldwide. For more information about the ADDF, visit

About the Association for Frontotemporal Dementia

The Association for Frontotemporal Dementias (AFTD) is a nationwide non-profit organization whose mission is to promote and fund research into finding the cause and cure for the frontotemporal dementias; to provide information, education, and support to persons diagnosed with frontotemporal dementias (FTD) and their families and caregivers; and to educate physicians and allied health professionals about FTD. In addition to providing funding for this drug discovery program, AFTD continues to fund basic and clinical research that is essential to improving our understanding of this relatively rare, but significant disease. For more information about The AFTD, visit

Contact Information